 Imidazoles
"Imidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
| Descriptor ID |
D007093
|
| MeSH Number(s) |
D03.383.129.308
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Imidazoles".
Below are MeSH descriptors whose meaning is more specific than "Imidazoles".
This graph shows the total number of publications written about "Imidazoles" by people in this website by year, and whether "Imidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 3 | 1 | 4 | | 1992 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 2 | 0 | 2 | | 1997 | 0 | 4 | 4 | | 1998 | 0 | 5 | 5 | | 1999 | 1 | 3 | 4 | | 2000 | 5 | 3 | 8 | | 2001 | 2 | 7 | 9 | | 2002 | 3 | 8 | 11 | | 2003 | 3 | 4 | 7 | | 2004 | 0 | 2 | 2 | | 2005 | 4 | 3 | 7 | | 2006 | 3 | 2 | 5 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 3 | 4 | | 2009 | 3 | 2 | 5 | | 2010 | 3 | 7 | 10 | | 2011 | 1 | 3 | 4 | | 2012 | 3 | 5 | 8 | | 2013 | 4 | 5 | 9 | | 2014 | 3 | 6 | 9 | | 2015 | 6 | 8 | 14 | | 2016 | 2 | 3 | 5 | | 2017 | 3 | 4 | 7 | | 2018 | 3 | 3 | 6 | | 2019 | 3 | 0 | 3 | | 2020 | 2 | 1 | 3 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Imidazoles" by people in Profiles.
-
Alzofon N, Jimeno A. Capmatinib for non-small cell lung cancer. Drugs Today (Barc). 2021 Jan; 57(1):17-25.
-
Kondapalli L, Worth S, Hawi R, Vachhani P, Arora G, Bhatia R, Lenneman CG. Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors. Vasc Med. 2020 06; 25(3):246-254.
-
Dimou A, Barron G, Merrick DT, Kolfenbach J, Doebele RC. Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma. BMC Cancer. 2020 Mar 04; 20(1):177.
-
Rossoff J, Huynh V, Rau RE, Macy ME, Sulis ML, Schultz KR, Burke MJ, Athale U, O'Brien MM, Gregory JJ, van der Sluis IM, Keller FG, Zwaan CM, Suttorp M, Hijiya N. Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol. 2020 04; 189(2):363-368.
-
Rule SA, Cartron G, Fegan C, Morschhauser F, Han L, Mitra S, Salles G, Dyer MJS. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). Leukemia. 2020 05; 34(5):1458-1461.
-
Moore HM, Savage HM, O'Brien C, Zhou W, Sokol ES, Goldberg ME, Metcalfe C, Friedman LS, Lackner MR, Wilson TR. Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. Mol Cancer Ther. 2020 01; 19(1):292-303.
-
Abramson VG, Oliveira M, Cervantes A, Wildiers H, Patel MR, Bauer TM, Bedard PL, Becerra C, Richey S, Wei MC, Reyner E, Bond J, Cui N, Wilson TR, Moore HM, Saura C, Krop IE. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. Breast Cancer Res Treat. 2019 Nov; 178(1):121-133.
-
Maher TM, Kreuter M, Lederer DJ, Brown KK, Wuyts W, Verbruggen N, Stutvoet S, Fieuw A, Ford P, Abi-Saab W, Wijsenbeek M. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respir Res. 2019; 6(1):e000422.
-
Alam MM, Trivett A, Meyer TJ, Oppenheim JJ. HMGN1 and R848 Synergistically Activate Dendritic Cells Using Multiple Signaling Pathways. Front Immunol. 2018; 9:2982.
-
Ng TL, Yu H, Smith DE, Boyle TA, York ER, Leedy S, Gao D, Aisner DL, Van Bokhoven A, Heasley LE, Hirsch FR, Camidge DR. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. Clin Lung Cancer. 2019 01; 20(1):e39-e51.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|